国产替罗非班在高龄急性冠状动脉综合征患者介入治疗中的应用

被引：9

作者：

陈忠

马根山

冯毅

罗丹

沈成兴

戴启明

丁建东

沈吉梅

机构：

[1] 东南大学附属中大医院心脏科

来源：

中国介入心脏病学杂志 | 2006年 / 06期

关键词：

冠状动脉疾病; 替罗非班; 治疗结果;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

目的评价高龄(≥70岁)非ST段抬高急性冠状动脉综合征(ACS)患者冠状动脉介入治疗(PCI)中应用国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班的安全性和近期疗效。方法108例行PCI的非ST段抬高ACS患者按年龄分为高龄组(≥70岁,42例)和非高龄组(<70岁,66例),分析两组基础资料特征、即刻手术成功率、出血和血小板减少发生率;观察住院和随访30天期间不良心血管事件(再发心绞痛、心肌梗死、心力衰竭及猝死)。结果高龄组甘油三酯、脂蛋白a高于非高龄组,体重指数和吸烟比例低于非高龄组(P均<0.05);高龄组多支病变比例高于非高龄组(71%比39%,P<0.01);两组PCI即刻成功率均为100%。高龄组发生小出血5例、血小板减少6例;非高龄组小出血2例,血小板减少2例;两组均无大出血发生。高龄组血小板减少及总副反应发生率高于非高龄组(P均<0.05),小出血发生率差异无统计学意义(P>0.05)。高龄组住院和随访期间再发心绞痛5例、心肌梗死1例、心力衰竭2例、猝死0例;非高龄组再发心绞痛7例、心力衰竭1例,无心肌梗死和猝死。两组间复合心血管事件发生率差异无统计学意义(P>0.05)。结论高龄非ST段抬高ACS患者PCI中应用国产替罗非班是安全的。

引用

页码：365 / 368

页数：4

共 9 条

[1]

American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Braunwald E,Antman EM,Beasley JW,et al. Circulation . 2002

[2]

Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. The PRISM-PLUS study investigators. The New England Journal of Medicine . 1998

[3]

Acomparision of aspirin plus tirofiban with aspirin plus heparinfor unstable angina. The Platelet Receptor Inhibition In Ischemic Syndrome Management(PRISM)Study Investigators. The New England Journal of Medicine . 1998

[4]

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction. Valgimigli M,Percoco G,Malagutti P,et al. The Journal of The American Medical Association . 2005

[5]

Diffuse alveolar hemorrhage followingadministrationof tirofibanina patient withacute coronarysyndrome:afatal complication. Yilmaz MB,Akin Y,Biyikoglu SF,et al. International Journal of Cardiology . 2004

[6]

Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion(a TACTICS-TIMI18substudy). Gibson M,Singh KP,Murphy SA,et al. The American Journal of Cardiology . 2004

[7]

for the TIMI investigators Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator,heparin and aspirin for acute myocardial infarction. Bovill EG,Terrin ML,Stump DC,et al. Annals of Internal Medicine . 1991

[8]

Analysis of bleeding complications associated withglycoproteinⅡb/Ⅲareceptors blockade in patients with high-risk acute coronarysyndromes:insightsfromthe PRISM-PLUS study. Huynh T,Piazza N,DiBattiste PM,et al. International Journal of Cardiology . 2005

[9]

Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Martinez-Rios MA,Rosas M,Gonzalez H,et al. The American Journal of Cardiology . 2004

← 1 →